Neurogene (NGNE) FCF Margin (2018 - 2024)
Neurogene (NGNE) reported FCF Margin of 1755.03% for Q2 2024, down 268581.42% quarter-over-quarter from 0.65% in Q3 2019.
Neurogene (NGNE) FCF Margin (2018 - 2024) Analysis & Trends
Neurogene has reported FCF Margin for 3 years, with the latest figure at 1755.03% in Q2 2024.
- For the quarter ending Q2 2024, FCF Margin changed N/A year-over-year to 1755.03%; the trailing twelve-month figure through Jun 2025 stood at 8050.59% (down 83168.0% YoY), and the FY2024 full-year result was 7711.24%, changed N/A from the prior year.
- FCF Margin for Q2 2024 stood at 1755.03%, down from 0.65% in the prior quarter.
- The five-year high for FCF Margin was 1755.03% in Q2 2024, with the low at 1755.03% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1,755.03% |
| Sep 30, 2019 | -0.65% |
| Jun 30, 2018 | 36.61% |